| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Comstock Inc.
13D/A
LODE · 205750409
|
5.2% |
10/16/2026
Event 10/14/2026
|
||||
| MAK Capital Fund LP | 5.2% | |||||
| Mak Capital One LLC | 5.2% | |||||
| Kaufman Michael A | 5.2% | |||||
|
Evotec SE
13D/A
EVO · 30050E105
|
7.1% |
5/1/2026
Event 4/29/2026
|
||||
| MAK Capital Fund LP | 7.1% | |||||
| MAK Capital One L.L.C. | 7.1% | |||||
| Michael A. Kaufman | 7.1% | |||||
| Schedule 13G · 6 securities · passive | ||||||
|
Standard BioTools Inc.
13G/A
LAB · 34385P108
|
6.7% |
5/15/2026
Event 3/31/2026
|
||||
| MAK Capital Fund LP | 6.7% | |||||
| MAK Capital One L.L.C. | 6.7% | |||||
| Michael A. Kaufman | 6.7% | |||||
|
ClearPoint Neuro, Inc.
13G/A
CLPT · 18507C103
|
6.3% |
5/15/2026
Event 3/31/2026
|
||||
| MAK Capital Fund LP | 6.3% | |||||
| Mak Capital One LLC | 6.3% | |||||
| Kaufman Michael A | 6.3% | |||||
|
Autolus Therapeutics plc
13G/A
AUTL · 05280R100
|
12.6% |
5/15/2026
Event 3/31/2026
|
||||
| MAK Capital Fund LP | 12.6% | |||||
| Mak Capital One LLC | 12.6% | |||||
| Kaufman Michael A | 12.6% | |||||
|
Protalix BioTherapeutics, Inc.
13G/A
PLX · 74365A309
|
4.5% |
3/30/2026
Event 3/24/2026
|
||||
| MAK Capital Fund LP | 4.5% | |||||
| Mak Capital One LLC | 4.5% | |||||
| Kaufman Michael A | 4.5% | |||||
|
Talkspace, Inc.
13G/A
TALK · 87427V103
|
4.2% |
3/12/2026
Event 3/9/2026
|
||||
| MAK Capital Fund LP | 4.2% | |||||
| MAK Capital One L.L.C. | 4.2% | |||||
| Michael A. Kaufman | 4.2% | |||||
|
DIRTT Environmental Solutions Ltd.
13G/A
DRTTF · 25490H106
|
4.7% |
2/13/2026
Event 12/31/2025
|
||||
| MAK Capital Fund LP | 4.7% | |||||
| MAK Capital One L.L.C. | 4.7% | |||||
| Michael A. Kaufman | 4.7% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.